Skip to main content
PolicySpeak
← All files
APS

Angelini Pharma SpA

Company · Italy · EU Transparency Register 544580951592-90

1
position filed
in the 673 files tracked
1
legislative file
of 673 tracked
1
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 673 consultation files tracked so far (58,314 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 1216 companies & groups on this site, they rank #854 by legislative files engaged, a count of participation, not a measure of influence.

0.2
declared lobbying FTE
self-declared
€50K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2023
in the register since

Declares membership of

Self-declared to the EU Transparency Register (snapshot 20 Oct 2026).

Register category
Companies & groups
Registered as
Angelini Pharma
Head office
Roma, Italy

Self-declared to the EU Transparency Register (snapshot 20 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Angelini in PolicySpeak: request access →

Follow Angelini Pharma SpA

An email when this organization files on a consultation we publish.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Work at Angelini Pharma SpA? so we know who speaks for it.

Their record over time

Angelini Pharma SpA filed 1 position on 3 Nov 2023, across 1 of the 673 legislative files tracked here, attaching a full position paper 1 time.

What they argued

Medicinal products for human usefiled 3 Nov 2023PDFsource

ANGELINI PHARMA POSITION PAPER ON THE GENERAL PHARMACEUTICAL LEGISLATION REVISION OCTOBER 2023 Angelini Pharma acknowledges the strategic objectives of the General Pharmaceutical Legislation (GPL) since it represents a unique opportunity to foster innovation, attract investments in life science, secure a crisis-resistant EU Regulatory ecosystem, and allow European patients to get access to medicinal products.

Opening of the attached position paper · the full paper is on the Commission’s record (source link above)

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put Angelini Pharma SpA next to another organization. Same files, same register facts, side by side. Compare →

Is this your organization?

Everything on this page comes from Angelini Pharma SpA’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.